202126-85-0

Basic information

• Product Name: 4-(3-FLUORO-BENZYL)-PIPERIDINE
• Synonyms: 4-(3-FLUORO-BENZYL)-PIPERIDINE;4-[(3-fluorophenyl)Methyl]piperidine
• CAS NO: 202126-85-0
• Molecular Formula: C₁₂H₁₆FN
• Molecular Weight: 193.26
• Mol File: 202126-85-0.mol

Chemical Properties

• Boiling Point: 278.583 °C at 760 mmHg
• Flash Point: 122.283 °C
• Appearance: /
• Density: 1.045 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-FLUORO-BENZYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-FLUORO-BENZYL)-PIPERIDINE(202126-85-0)
• EPA Substance Registry System: 4-(3-FLUORO-BENZYL)-PIPERIDINE(202126-85-0)

Safety Data

• Hazardous Substances Data: 202126-85-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Fluoro-benzyl)-piperidine is used as a key intermediate in the synthesis of methylaspartate receptor antagonists. These antagonists possess analgesic activity, which is particularly effective in managing neuropathic pain. The compound's structure allows for the development of targeted therapies with fewer side effects, offering a promising avenue for pain management in various conditions.

InChI:InChI=1/C12H16FN/c13-12-3-1-2-11(9-12)8-10-4-6-14-7-5-10/h1-3,9-10,14H,4-8H2

Upstream product

• 1121-86-4 1-Fluoro-3-iodobenzene 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 782504-42-1 (R,S)-(3-fluorophenyl)(pyridin-4-yl)methanol 
• 872-85-5 pyridine-4-carbaldehyde 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 
• 1412978-66-5 benzyl 4-(3-fluorobenzylidene)piperidine-1-carboxylate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 456-42-8 m-fluorobenzyl chloride 
• 63909-57-9 3-fluoro-1-diethylphosphonomethyl-benzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 193203-93-9 1-benzyl-4-(3-fluorobenzylidene)piperidine 

Downstream Products

• 1412978-62-1 2-(1-ethylpiperidine-4-ylmethyl)-4-fluorobenzenesulfonyl chloride 
• 1412978-64-3 1-ethyl-4-(3-fluorobenzyl)piperidine 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

METHODS OF TREATING LIVER DISEASES

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

NEW BENZOYL UREA DERIVATIVES

The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C1-C4 alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, Cs

2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS

2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases.

NR2B-Selective N-Methyl-D-aspartate Antagonists: Synthesis and Evaluation of 5-Substituted Benzimidazoles

Two classes of 5-substituted benzimidazoles were identified as potent antagonists of the NR2B subtype of the N-methyl-D-aspartate (NMDA) receptor. Selected compounds show very good selectivity versus the NR2A, NR2C, and NR2D subtypes of the NMDA receptor as well as versus hERG-channel activity and α1-adrenergic binding. Benzimidazole 37a shows excellent activity in the carrageenan-induced mechanical hyperalgesia assay in rats as well as good pharmacokinetic behavior in dogs.